<DOC>
	<DOC>NCT01302873</DOC>
	<brief_summary>This study will assess the efficacy of a two week treatment with BGG492 in patients with chronic subjective Tinnitus.</brief_summary>
	<brief_title>Study of BGG492 in Patients With Chronic Subjective Tinnitus</brief_title>
	<detailed_description />
	<mesh_term>Tinnitus</mesh_term>
	<criteria>Patients diagnosed with THI (Tinnitus Handicap Inventory) severity grade 3, 4 or 5 (moderate, severe or catastrophic), chronic (&gt; 6 months and &lt; 36 months) subjective tinnitus Willing to abstain from activities that require focused attention, e.g. driving a car or other vehicles, operating machines or engaging in potentially dangerous activities that require focused attention and intact physical balance Willing and able to refrain from engaging in activities or work involving loud noise exposure Patients diagnosed with tinnitus of THI severity grade equal to 2 or 1 Patients with diagnosis of intermittent or pulsatile tinnitus Patients who have tinnitus as a concomitant symptom of a treatable otological disease (such as otitis media, Meni√®re's disease, otosclerosis), neurological tumors or/and have temporomandibular joint disorders Patients with a history of frequent middle ear infections (&gt; 3 infections per year during the last 3 years) Patients with diagnosed anxiety disorders, depression, schizophrenia or other significant psychiatric diseases requiring current drug treatment or patients who required treatment in the previous 3 months for these diseases. Patients with current unilateral or bilateral hearing loss of 75 dB or more in one or more tested frequencies (125 Hz, 250 Hz, 1 kHz, 2 kHz, 4 kHz, 6 kHz, 8 kHz) Patients with Vestibular Schwannoma Patients with a cochlear implant Patients with regular intake of central nervous system acting drugs for the treatment of tinnitus in the previous 6 months prior to initial dosing Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Tinnitus</keyword>
	<keyword>AMPA Receptor antagonist</keyword>
</DOC>